Skip to content
Navigate to homepage - Cerba Research
Resource Library

Created:

Challenges of Covid-19 Testing: Which Test to Use?

Are you using the right Covid-19 test? In the race to contain the COVID-19 pandemic, efficient detection of SARS-CoV-2 was and still remains the cornerstone. On January 23, the first in-house RT-PCR assay was published, quickly followed by the development of multiple commercial kits.

During the webinar, our Cerba biologists will walk participants through the overview of our available testing, discuss the reliability of tests, the current limits in Covid-19 testing, and which sample is the most efficient in each case.

Lastly, Cerba Research’s partner Fulgent will discuss NGS testing and how much we know about the analysis of the virus and its mutations.

Resource Library

Created:

COVID-19 Testing at Cerba Research

In light of the global COVID-19 (SARS-Cov-2) pandemic, the search for a treatment or vaccine has become urgent and critical. Cerba Research, together with all its partners, is widely using COVID-19 diagnostic tests to detect the virus in patients. In addition, we are assisting in making testing available in clinical trials globally.


Please, feel free to reach out to us if our COVID-19 capabilities and overall understanding of coronavirus pathogenesis can help advance the development of your treatment.

Covid-19 Testing at Cerba Research

Click here to download the Flyer
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Created:

HISTOSELECT: How to Overcome Challenges in Antibody Selection?

HISTOSELECT®: The number one solution for direct screening of large numbers of antibodies by immunohistochemistry (IHC).

HistoSelect

Click here to download the flyer
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your research

Contact Us
Resource Library

Created:

CerbACT Asia – Center of Excellence in Immuno-Oncology

CerbACT Asia empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research & clinical development strategies, combining the strengths of Cerba Research and ACT Genomics. We are enabled by cutting edge technologies in Flow Cytometry (FCM), Immunohistochemistry (IHC), and PBMC/cell isolations, while functioning as a central laboratory in the APAC region. Working with biotech, pharma, government and nongovernmental organizations, our team is ready to turn precision medicine into action!

CerbACT Asia

Click here to download the flyer
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Created:

Next Generation Biomarker Discovery

Strong & Sustainable Partnership

Learn how Cerba Research and Fulgent are enhancing genomic data in clinical trials for better patient outcomes across all phases through their NGS services. In this presentation, you’ll learn how we’re accelerating precision medicine with next generation biomarker discovery through our partnership and specific expertise in oncology, rare disease, CNS, metabolic, and infectious diseases.

Resource Library

Created:

Cerba Research’s Multi-Omics Approaches in Hematological Malignancies

Hematological malignancies originate from the uncontrolled growth of hematopoietic and lymphoid tissues. These biologically and clinically heterogeneous disorders account for 6.5% of all cancers worldwide, and for approximately 9.5% of newly diagnosed cancers every year.

Due to the high level of heterogeneity in cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional, and metabolic alterations of hematological diseases, integrated multi-omics analyses are needed to improve clinical outcomes.

At Cerba Research, we aim to bring a multi-modal approach to precision medicine to disease. From discovery to clinical development, we provide world-class teams and capabilities worldwide to help you in your quest for novel treatment against hematological malignancies.

Brochure – Cerba Research's Multi-Omics Approaches in Hematological Malignancies

Click here to download the brochure
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your research

Contact Us
Resource Library

Created:

Turning Precision Medicine into Action in Immuno-Oncology

The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.

In this webinar our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.

Speakers

  • Jérôme Sallette, PhD, CSO Cerba Research
  • Shu Jen Chen, PhD, CSO ACT Genomics
  • Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
  • George Wei, PhD, Vice President R&D ACT Genomics
  • Renaud Burrer, PhD, Head of Histopathology Cerba Research
  • Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research

Submit your information below to watch the webinar or to download the slide deck to receive our expert’s insights.

Cerba Research – Webinar – CerbACT turning precision medicine inot action in immuno oncology

Cerba Research - Webinar - CerbACT turning precision medicine inot action in immuno oncology - Thumbnail playbutton
Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts to see how we can help advance your clinical trial

Contact Us